<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-04-30T02:26:13Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/2455-5363.000019">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/2455-5363.000019</identifier>
									<datestamp>2018-12-11</datestamp>
									<setSpec>PTZ.GJIDCR:VOL4</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Emergent of Colistin Resistant Enterobacteriaceae carrying the mcr-1 gene among clinical isolates from patients in an Argentine hospital: Clinical and microbiological aspects
										</dc:title><dc:creator>J Nievas</dc:creator><dc:creator> D Torres</dc:creator><dc:creator> F Nicola</dc:creator><dc:creator> P Bonvehí</dc:creator><dc:creator> L Scocozza</dc:creator><dc:creator> W Alcalá</dc:creator><dc:creator> F Herrera</dc:creator><dc:creator> S Relloso</dc:creator><dc:creator>J Smayevsky</dc:creator><dc:description>&lt;p&gt;The recent emergence of multidrug-resistant (MDR) or extremely drug-resistant (XDR) Gram-negative bacteria has renewed interest in colistin (Polymyxins, a family of cationic polypeptide antibiotics) as a last-resort in the treatment of severe bacterial infections [1,2], despite being a drug with potential serious adverse events (mainly high risk of nephrotoxicity) [3,4]. Acquired resistance to polymyxins is generally associated with chromosomal mutations [5,6].&amp;nbsp;&lt;/p&gt;</dc:description>
										<dc:publisher>Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications</dc:publisher>
										<dc:date>2018-12-11</dc:date>
										<dc:type>Letter to Editor</dc:type>
										<dc:identifier>https://doi.org/10.17352/2455-5363.000019</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © J Nievas et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
